New articles in the GANM Library: COVID-19 vaccine, gender equality, and clinical data

Jul 21, 2020

Dear GANM community,

 

As we move towards the end of July and with research being published daily, we would like to present to you three new articles centered around COVID-19.

 

 

Bilaloglu, S., Aphinyanaphongs, Y., Jones, S., Iturrate, E., Hochman, J., & Berger, J.S. (2020). Thrombosis in hospitalized patients with COVID-19 in a New York City health system. JAMA. doi:10.1001/jama.2020.13372

 

Recent clinical data have shown that individuals diagnosed with COVID-19 are at an increased risk of thrombosis. In a recent study, researchers set out to understand the incidence of thrombosis as well as risk factors for venous and arterial thrombotic events in hospitalized patients. Findings include an all-cause mortality of 24.5% and approximately 16% of hospitalized patients having a thrombotic event. (Click here to read more)

 

 

Madgavkar, A., White, O., Krishnan, M., Mahajan, D., & Azcue, X. (2020). COVID-19 and gender equality: Countering the regressive effects. McKinsey Global Institute. https://www.mckinsey.com/featured-insights/future-of-work/covid-19-and-gender-equality-countering-the-regressive-effects#

 

Gender inequalities have translated to women being more vulnerable to COVID-19. In a recent article published by the McKinsey Global Institute researchers showed the impact of COVID-19 on women in terms of jobs, livelihood, and why we need to take action now. Recommended interventions include new policies on gender equality, childcare, biases, and financial inclusion. (Click here to read more)

 

Zhu, F., Guan, X., Li, Y., Huang, J., Jiang, T., Hou,L., Li, J., Yang, B., Wang, L., Wang, W., Wu, S., Wang, Z., Wu, X., Xu, J., Zhang, Z., Jia, S., Wang, B., Hu, Y., Liu, J., Zhang, J., Qian, X., Li, Q., Pan, H., Jiang, H., Deng, P., Gou, J., Wang, X., Wang, X, & Chen, W. (2020). Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: A randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. https://doi.org/10.1016/S0140-6736(20)31605-6

 

We now turn our attention to a recently published article on the assessment of a SARS-CoV-2 vaccine published in The Lancet. In this randomized, double-blind, phase 2 trial researchers found that the vaccine produced statistically significant immune responses in the majority of recipients after a single immunization. These findings support testing in a phase 3 trial in health adults which is to be completed over the next few months. (Click here to read more)


Other news